CHELSEY WINNINGHAM: Open Payments
NPI 1083481139 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$458 in 26 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $49 · 2025 $458
Food & beverage: $458
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $93 |
| Novo Nordisk Inc | 4 | $71 |
| ABBVIE INC. | 4 | $67 |
| Amgen Inc. | 3 | $59 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| ABIOMED | 1 | $17 |
| PFIZER INC. | 1 | $17 |
| SANOFI-AVENTIS U.S. LLC | 1 | $15 |
Products named: AIRSUPRA, Rybelsus, UBRELVY, OTEZLA, TRELEGY ELLIPTA, JARDIANCE, REZDIFFRA, REPATHA.
Industry payments across TX — which companies pay providers there.
